Three-month Dapivirine Ring
- Acts against: HIV-1
- Delivery method: Silicone elastomer vaginal ring
- Active ingredient: Dapivirine, an ARV
- Length of action: Three months
- Status: One Phase I trial completed
Why is the three-month dapivirine ring important?
Current HIV prevention methods are used at the time of sex or daily, with a monthly version of the dapivirine vaginal ring on the horizon. An even longer-acting dapivirine ring that could be used for three months at a time would further expand women’s options, offer greater convenience and reduce annual costs.
How does the three-month dapivirine ring work?
The ring is made of a flexible silicone matrix polymer and contains dapivirine, an ARV that is slowly released over the course of three months.
Women would insert the ring themselves into the vagina and replace it every three months.
What is its development history?
Using our monthly dapivirine ring as a platform technology, IPM began developing the 3-month dapivirine ring in 2014.
What is its clinical history?
In late 2017, IPM and its clinical trial partner the Microbicide Trials Network initiated MTN-036/IPM 047, a Phase I randomized trial assessing the safety and pharmacokinetics of long-acting vaginal rings containing different amounts of dapivirine when used for approximately three months in 48 healthy, HIV-uninfected women ages 18-45 who are not pregnant in the United States. Participants were randomly assigned to one of three groups: one group used a vaginal ring designed for three-month use that contained 100 mg dapivirine; one group used a ring also designed for three-month use that contained 200 mg dapivirine; and for comparison, one group used the one-month ring containing 25 mg dapivirine. Data analysis has been delayed due to the COVID-19 pandemic, with results expected by early 2021.
What are the next steps for the three-month dapivirine ring?
Results from the MTN-036/IPM 047 study will help determine next steps for the product. IPM hopes to submit regulatory applications for the three-month dapivirine ring in late 2022.
Who is IPM currently partnering with to develop and test the ring?
- ARV license: Janssen Sciences Ireland UC for dapivirine
- Development: Queens University Belfast
- Manufacturing: QPharma
- Clinical trial: Microbicide Trials Network
Where can I learn more?
- Our lead ARVs: Dapivirine
- Press release: IPM’s Three-month HIV Prevention Vaginal Ring Begins First Clinical Trial
- Scientific publications